Clopidogrel (Plavix) is the cornerstone of dual antiplatelet therapy (DAPT) after PCI and stent placement. The CURE trial established its role in NSTEMI; current guidelines recommend 12 months of DAPT after drug-eluting stents.
Research summaries are AI-generated from open-access peer-reviewed literature (PubMed Central, Cochrane, AHA/ACC). Content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.